Western Midstream Partners announced a quarterly cash distribution of $0.93 per unit for Q3 2026, consistent with the previous quarter. The distribution, annualized at $3.72 per unit, will be paid on November 13, 2026, to unitholders recorded by November 2. The company plans to release its Q3 financial results on November 4, followed by a conference call on November 5 to discuss performance. This steady distribution reflects Western Midstream's stable cash flow from fee-based contracts, minimizing exposure to commodity price fluctuations.
Western Midstream Partners announced a quarterly cash distribution of $0.93 per unit for Q3 2026, maintaining its steady payout. For readers following the Energy sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 79 priced US Energy stocks, 35 rose and 43 fell. Notable movers include RUN (Sunrun Inc) at USD 6.91 with a 1-day change of -5.34% and 100% buy order activity, RIG (Transocean Ltd) at USD 5.92 up 5.25% with 100% buy orders, and VAL (Valaris Limited Common Shares) at USD 89.65 up 5.08%, with a typical hold time of 5 days on Pluang.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
